In 2023, Novartis completed its transformation into a “pure-play” innovative medicines business. We have a clear focus onfour core therapeutic areas(cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple signifi...
including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; our performance on and ability to comply with environmental, social and governance measures and requiremen...
6月12日,Novartis公告拟以35亿美元总价款收购Chinook Therapeutics,重点瞄准了旗下两款用于治疗IgA肾病的分子。 https://www.novartis.com/news/media-releases/novartis-bolsters-innovative-medicines-strategy-and-renal-pipeline-agreement-...
Drug discovery efforts at Novartis have delivered an industry-leading pipeline of drug candidates to address the emerging threat of resistance. Two antimalarials in development, KAF156 (ganaplacide) and KAE609 (cipargamin), offer new mechanisms of action against the disease and have the potential...
Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines
In 2023, Novartis completed its transformation into a “pure-play” innovative medicines business. We have a clear focus onfour core therapeutic areas(cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple signifi...
We have a clear focus on four core therapeutic areas (cardiovascular-renal-metabolic, immunology, neuroscience and oncology), with multiple significant in-market and pipeline assets in each of these areas, that address high disease burden and have substantial growth potential. In addition to two ...